| Literature DB >> 33753021 |
S Koirala1, S Borisov2, E Danila3, A Mariandyshev4, B Shrestha5, N Lukhele6, M Dalcolmo7, S R Shakya8, S Miliauskas9, L Kuksa10, S Manga11, A Aleksa12, J T Denholm13, H B Khadka14, A Skrahina15, S Diktanas16, M Ferrarese17, J Bruchfeld18, A Koleva19, A Piubello20, G S Koirala21, Z F Udwadia22, D J Palmero23, M Munoz-Torrico24, R Gc25, G Gualano26, V I Grecu27, I Motta28, A Papavasileiou29, Y Li30, W Hoefsloot31, H Kunst32, J Mazza-Stalder33, M-C Payen34, O W Akkerman35, E Bernal36, V Manfrin37, A Matteelli38, H Mustafa Hamdan39, M Nieto Marcos40, J Cadiñanos Loidi41, J J Cebrian Gallardo42, R Duarte43, N Escobar Salinas44, R Gomez Rosso45, R Laniado-Laborín46, E Martínez Robles47, S Quirós Fernandez48, A Rendon49, I Solovic50, M Tadolini51, P Viggiani52, E Belilovski2, M J Boeree31, Q Cai53, E Davidavičienė54, L D Forsman18, J De Los Rios55, J Drakšienė16, A Duga56, S E Elamin39, A Filippov2, A Garcia23, I Gaudiesiute9, B Gavazova57, R Gayoso7, V Gruslys3, J Jonsson58, E Khimova4, G Madonsela59, C Magis-Escurra31, V Marchese38, M Matei60, C Moschos29, B Nakčerienė54, L Nicod33, F Palmieri26, A Pontarelli61, A Šmite10, M B Souleymane20, M Vescovo23, R Zablockis3, D Zhurkin15, J-W Alffenaar62, J A Caminero63, L R Codecasa17, J-M García-García64, S Esposito65, L Saderi66, A Spanevello67, D Visca67, S Tiberi68, E Pontali69, R Centis70, L D'Ambrosio71, M van den Boom72, G Sotgiu66, G B Migliori73.
Abstract
The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally. This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year. All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines. Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10-80% in the remaining 5 countries). The drug-resistance pattern of the patients was severe (>30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3-7) in the overall cohort and 6 (4-8) among patients with a final outcome). For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13-23) (in days 553 (385-678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30-90) days for the whole cohort and 60 (30-100) for patients with a final outcome and, respectively, of 55 (30-90) and 60 (30-90) days for culture conversion. Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up.Entities:
Keywords: Bedaquiline; Delamanid; MDR-TB; Prevention of TB sequelae; Treatment outcomes; Tuberculosis
Mesh：
Substances：
Year: 2021 PMID： 33753021 DOI： 10.1016/j.pulmoe.2021.02.006
Source DB: PubMed Journal: Pulmonology ISSN： 2531-0429